Should You Buy Ideaya Biosciences Inc (IDYA) Stock on Monday?

Overall market sentiment has been down on Ideaya Biosciences Inc (IDYA) stock lately. IDYA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Ideaya Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IDYA!

See Full IDYA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With IDYA Stock Today?

Ideaya Biosciences Inc (IDYA) stock is lower by -1.11% while the S&P 500 is up 0.09% as of 12:03 PM on Monday, Nov 13. IDYA is lower by -$0.32 from the previous closing price of $29.39 on volume of 64,275 shares. Over the past year the S&P 500 has gained 11.67% while IDYA is up 71.00%. IDYA lost -$1.94 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Ideaya Biosciences Inc click here.

More About Ideaya Biosciences Inc

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Click Here to get the full Stock Report for Ideaya Biosciences Inc stock.